Oh, Yale.
Yale, Yale, Yale.
It is widely acknowledged that the State of Connecticut is more aptly referred to as “Corrupticut,” but now we know for sure that the heart of the beast lies directly within the medical and research complex of Yale University.
As if it wasn’t bad enough that they are co-conspirators in the medical scandal/fraud/RICO/homicide known as Lyme disease. Now they are coming up with ways to further cover their tracks, in a strategy that’s so poorly disguised as vaccine development that it’s frankly a little awkward.

By now, we should all be well aware of the fact that Yale’s Erol Fikrig and Richard Flavell own the only FDA-valid method for the diagnosis of Lyme disease, a la U.S Patent 5,618,533:

http://www.google.com/patents/US5618533

“Diagnostic means and methods for Lyme disease comprising B. burgdorferi flagellin polypeptides and antibodies. Compositions and methods comprising neuroborreliosis-associated antigens useful for the detection, treatment and prevention of neuroborreliosis, arthritis, carditis and other manifestations of Lyme disease.”

This is a “validation” according to the FDA’s Guidelines on the Validation of Bioanalytical Methods; the gene product is not cross reactive, the vast majority of Lyme victims produce this antibody in response to B. burgdorferi, and it is the first antibody to show up. FYI, it’s band 41 on the Western blot.
We should also recall that Yale did not use their own test—the only VALID method—to assess the outcome of their other, later, patent for the LYMErix vaccine.
Yale’s LYMErix Patent, 5,747,294:

http://www.google.com/patents/US5747294

Compare the dates on these two patents. Put quite simply, this is the Qui Tam complaint. Yale did not use their flagellin method to qualify LYMErix…Because Yale, et al, knew LYMErix would not prevent Lyme. Especially Fikrig, since he later wrote about how OspA would not work as a vaccine, anyway, due to antigenic variation or “selection pressure.”

This scientific conclusion means the same thing as “You can’t have a vaccine against Relapsing Fever, since the nature of the relapse is antigenic variation. Vaccines and antibodies do no good.”
So, they knew how to diagnose Lyme, and they made a “vaccine” that they knew would cause the disease, and because they knew, they did not use their own, earlier patent, to assess the vaccine outcomes. Cool, huh?

For more information on validations and why this is a problem, see Chapter 1 of CrymeDisease here: http://www.actionlyme.org/CRYMEDISEASE_CHP1.htm

Now we come to Yale’s Office of Cooperative Research.
http://ocr.yale.edu/new-ventures

Here is their load of crap description:

“Since its founding in 1982, the Yale Office of Cooperative Research (OCR) has built a significant portfolio of inventions and patents and has grown into an engine of regional economic development. Its mission is to facilitate the translation of research from Yale’s labs into products and services that benefit society. OCR is recognized as a leading force for catalyzing economic growth by identifying, counseling and nurturing early-stage technologies and guiding the transition into robust companies.”

Translation: Through the prestige of our Ivy League status and the wealth and connections of our extensive alumni network and relationships with Pharma, government, foreign governments, insurance, organized crime, etc., we have built a multi-billion dollar corporate patenteering factory to further increase our considerable wealth with no regard for anyone but Yale and its stakeholders.
Simply follow the link to their spin-off, “VaxInnate” to see what the criminals are up to.
http://vaxinnate.com/about-us/

“VaxInnate, a privately-held biotechnology company located in Cranbury, NJ, is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production. This vaccine platform is based on Toll-like Receptor (TLR) technology, which dramatically improves vaccine immunogenicity and efficacy. VaxInnate’s vaccines focus on infectious diseases, including seasonal and pandemic flu, dengue and Clostridium difficile.”

Further:

“VaxInnate has developed a dramatically improved vaccine platform and vaccines for infectious diseases, including seasonal and pandemic flu, dengue and Clostridium difficile. The company was founded in 2002 by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity.”

http://vaxinnate.com/technology-platform/

Wait—Who was that? Richard? Richard Flavell? THE Richard Flavell, of Flagellin fame? The same Richard Flavell who patented the flagellin test method and then didn’t use it to assess the outcomes for his other patent, LYMErix?

Would someone please arrest this guy, already?

“VaxInnate’s proprietary Toll-like Receptor (TLR) technology genetically fuses vaccine antigens to the bacterial protein flagellin. This triggers an immune response in the innate immune system. Using recombinant DNA techniques we are able to produce unlimited quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.”

Got that? They will be able to produce “unlimited quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.”

After the LYMErix fiasco, these guys shouldn’t be trusted to feed the mice they experiment on, let alone come up with new “vaccines.” Whatever they have up their sleeve here, it can’t be good.

For 13 years since LYMErix has been off the market, we have been waiting for the Department of Justice to do its job and prosecute the LYMErix and Dearborn fraud. Thirteen years, and how many millions of people suffering because these guys were simply let off the hook? What new fraud are we going to allow them to perpetrate against humanity? Why are they still allowed in a lab?

It’s bad enough that the DOJ is ignoring this crime and allowing Yale’s mad scientists to continue developing vaccines. But what could be the worst case scenario?

If they were to use borrelia flagellin (knowing that most people produce an immune response to it) to rapidly vaccinate the world against flu or other common nuisances, everyone and their brother, uncle, cousin, dog, cat, hamster, evil twin and imaginary friend will test positive for band 41—instantly invalidating their earliest Lyme patent and solidifying Yale’s place as the lobby for the main office of Hell.

I certainly wouldn’t put it past them.
Stay tuned for my follow-up entry on the first step to take if you are a victim of Yale’s Lyme fraud.

Categories: Activism, Lyme Disease, Vaccines

Tags: Fikrig, Flavell, Lyme, Lyme disease, LYMErix, OspA, vaccines, validation, Vaxinnate, Western blot, yale